Funding
← Back to your selection

HanKang Capital

Activity from announced rounds

Activity in this selectionmario-wettengel-1fd25234
Rounds participated in
2
Confirmed lead rounds
—
2 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$170M
2 disclosed · full round size, not this investor’s share

By stage

Series A1
Series C+1

By primary sector

Biotech2

By country

China1
United States1

Rounds

2 in this selection
AusperBio

Develops oligonucleotide therapeutics targeting chronic hepatitis B

$120MSeries C
Role not disclosed
Vivacta Biotechnology

Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases

$50MSeries A+
Role not disclosed